Current cell-surface targets being explored for targeted therapy of AML by antibody or CAR-T approaches include CD33, CD45, CD123, FLT3, Lewis-Y, and CLL-1 [reviewed in (7)]. Here, CD33 is linked to acute myeloid leukemia.